NEOS Investment Management LLC Sells 2,738 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

NEOS Investment Management LLC cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 51.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,563 shares of the biopharmaceutical company’s stock after selling 2,738 shares during the quarter. NEOS Investment Management LLC’s holdings in Alnylam Pharmaceuticals were worth $1,169,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Arvest Bank Trust Division bought a new stake in Alnylam Pharmaceuticals in the third quarter valued at approximately $215,000. GSA Capital Partners LLP bought a new stake in Alnylam Pharmaceuticals during the third quarter worth about $217,000. Rothschild Investment LLC boosted its position in shares of Alnylam Pharmaceuticals by 53,800.0% during the 3rd quarter. Rothschild Investment LLC now owns 1,078 shares of the biopharmaceutical company’s stock worth $492,000 after acquiring an additional 1,076 shares in the last quarter. Merit Financial Group LLC lifted its position in shares of Alnylam Pharmaceuticals by 123.9% during the 3rd quarter. Merit Financial Group LLC now owns 4,232 shares of the biopharmaceutical company’s stock worth $1,930,000 after buying an additional 2,342 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Alnylam Pharmaceuticals by 2.0% in the third quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock valued at $6,185,846,000 after buying an additional 268,313 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals News Summary

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Company reported ~ $3.0B in 2025 revenue (≈81% YoY) with Q4 net product revenue of $995M and a 151% surge in the TTR franchise — evidence of accelerating commercial momentum that supports longer‑term growth expectations. Alnylam Pharmaceuticals (ALNY) Reports $3B 2025 Revenue Driven by 151% TTR Franchise Surge
• Positive Sentiment: Canaccord Genuity raised its price target to $429, signaling stronger upside in analysts’ models and providing support for the stock’s valuation case. Canaccord Genuity Group Increases Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $429.00
• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating, and Freedom Capital upgraded ALNY to “Strong Buy” (reported via Zacks), adding buy‑side endorsement that could attract momentum investors. HC Wainwright Reaffirms “Buy” Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) Freedom Capital Upgrade via Zacks
• Neutral Sentiment: Some analysts trimmed targets after the latest reports while still expressing confidence in 2026 growth — a mixed read that leaves upside intact but tempers near‑term estimates. Analysts Trim Alnylam Pharmaceuticals, Inc. (ALNY) Targets but Keep Faith in 2026 Growth
• Neutral Sentiment: Independent valuation pieces highlight a divergence between recent share‑price performance and bullish fair‑value models — useful context for investors debating entry points. Assessing Alnylam Pharmaceuticals (ALNY) Valuation As Mixed Share Price Returns Meet Bullish Fair Value Models
• Negative Sentiment: Insider selling picked up this week: an EVP sold ~$607,447 of stock, and two other officers (Kevin Joseph Fitzgerald and Pushkal Garg) sold shares (2,041 and 2,242 shares respectively). Insider sales can create short‑term sentiment pressure even if they are routine. Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $607,446.72 in Stock Kevin Joseph Fitzgerald Sells 2,041 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Pushkal Garg Sells 2,242 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock opened at $336.19 on Friday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $495.55. The firm has a market capitalization of $44.59 billion, a P/E ratio of 196.60 and a beta of 0.35. The business’s fifty day simple moving average is $366.89 and its 200 day simple moving average is $422.44. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $0.82 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.61). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The company had revenue of $1.10 billion during the quarter, compared to the consensus estimate of $1.16 billion. During the same period in the prior year, the firm posted ($0.65) EPS. The business’s revenue was up 84.9% on a year-over-year basis. As a group, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Jeffrey V. Poulton sold 2,780 shares of the business’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $362.87, for a total value of $1,008,778.60. Following the sale, the executive vice president directly owned 57,465 shares in the company, valued at approximately $20,852,324.55. The trade was a 4.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Tolga Tanguler sold 1,959 shares of the stock in a transaction on Friday, February 13th. The stock was sold at an average price of $310.08, for a total value of $607,446.72. Following the sale, the executive vice president owned 31,769 shares in the company, valued at approximately $9,850,931.52. This represents a 5.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 36,578 shares of company stock worth $12,416,105 in the last three months. Corporate insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ALNY. Jefferies Financial Group cut their price target on shares of Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating on the stock in a report on Thursday, October 30th. Canaccord Genuity Group boosted their price target on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a research note on Tuesday. Truist Financial dropped their price objective on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. Wall Street Zen cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. Finally, Weiss Ratings raised Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday, January 15th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $477.96.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.